AstraZeneca to Invest in New Manufacturing Facility for Injectable Drug - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca to Invest in New Manufacturing Facility for Injectable Drug


AstraZeneca plans to invest $190 million in a new facility at its global manufacturing site in Macclesfield, United Kingdom, to continue production of Zoladex, an injectable treatment for patients with prostate cancer, the company announced in a press release. Construction will begin in 2013 and is due to be completed by 2016. The investment secures 300 existing Zoladex jobs at the site and will create more than 200 temporary jobs during the construction and commissioning phase between now and early 2017.

Zoladex, a widely prescribed luteinizing hormone-releasing hormone analog (LHRHa) therapy administered by a subcutaneous injection, has been manufactured at AstraZeneca’s Macclesfield plant for more than 25 years. It continues to be an important asset in AstraZeneca’s oncology portfolio and is currently the company’s fifth largest selling brand with annual sales in the region of $1 billion.

As a sterile subcutaneous injectable product, Zoladex is manufactured under highly specialized conditions, following a complex, multistage formulation process. This requires a range of high-specification equipment in a controlled operating environment to ensure aseptic production. The continued global demand for Zoladex, particularly in Japan and emerging markets including China and Russia, has resulted in the decision to invest in replacing some of the existing facilities where the medicine is currently produced at the Macclesfield site.

“Having considered a number of options globally, we believe it is the right choice to build the new facility in Macclesfield, which has been home to Zoladex manufacturing­—and the expertise that goes along with it—for many years,” said David Smith, executive vice-president of operations at AstraZeneca, in the press release.

Source: AstraZeneca

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here